NCT06718257View on ClinicalTrials.gov

Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

May 31, 2025

Conditions
Cholangiocarcinoma
Interventions
DRUG

Gemcitabine combined with cisplatin or oxaliplatin

Gemcitabine (1000 mg/m², day 1 and 8) and cisplatin (75 mg/m², day 1) or oxaliplatin (85 mg/m², day 1)

DRUG

Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors

Gemcitabine (1000 mg/m², day 1 and 8), cisplatin (75 mg/m²; day 1) or oxaliplatin (85 mg/m²; day 1), PD-1/L1 agents (200 mg; day 1), and TKI inhibitors (8 mg; per day)

Trial Locations (1)

310009

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER